香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，本集團旗下深圳中山婦產醫院新院區自2026年2月6 日起開始試運營。新院區地處深圳市中心區域，總建築面積達4萬平方米，規模約為原院 區的四倍。新院區的啟用為深圳中山婦產醫院業務的持續發展奠定了堅實基礎，同時有 力推動了醫院向VIP服務、特色專科以及國際醫療部等專項服務領域拓展。伴隨新院區啟 用，本集團深圳業務保持強勁增長勢頭，2026年前兩個月取卵週期（「OPU週期」）較2025 年同期增長18%。 在美國，本集團旗下通過管理服務協議實施管控的HRC Fertility診所，2026年前兩個月的 OPU週期較2025年同期增長約38%。此增長乃主要由於加州參議院第729號法案（「SB729 法案」）項下的體外受精(IVF)保險保障自2026年1月起正式實施後，當地患者需求增加所 致。該法案原定於2025年7月前後生效，後推遲實施。根據SB729法案，員工規模超過100 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 5,000,000,000 | | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 ...

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in relation to Jinxin Reproductive Medicine (01951.HK), indicating a reduction of 626,000 shares on February 27, while there were two days of net increases totaling 4.5723 million shares over the last five trading days [1] - Over the past 20 trading days, Jinxin Reproductive Medicine experienced net increases in southbound funds for 12 days, accumulating a total of 9.4858 million shares [1] - As of now, southbound funds hold 1.463 billion shares of Jinxin Reproductive Medicine, representing 53.03% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [1] - The company's services are mainly provided in China and the United States [1]

Core Viewpoint - Jinxin Healthcare Industry Group Limited has submitted an application for listing on the Hong Kong Stock Exchange, aiming to enter the capital market with the support of CICC and GF Securities as joint sponsors [1][4]. Group 1: Company Overview - Jinxin Healthcare, leveraging over 70 years of medical experience from Jinxin Group, entered the elderly care sector in 2011 and has established or acquired 23 medical and elderly care facilities by September 30, 2025, covering the Sichuan-Chongqing region, Yangtze River Delta, and Greater Bay Area [3][8]. - The company offers a comprehensive range of services including accommodation, professional nursing, nutritional management, social entertainment, medical services, rehabilitation assistance, and personalized on-demand services, extending its reach through community and home-based elderly care [3][8]. Group 2: Financial Performance - In terms of revenue, Jinxin Healthcare reported approximately 489 million yuan for the year 2023, with a projected increase to about 605 million yuan in 2024, representing a year-on-year growth of 23.7%. For the first nine months of 2025, revenue reached approximately 547 million yuan, showing growth compared to 448 million yuan in the same period of 2024 [3][8]. - The company's profit for the year 2023 was 27.06 million yuan, which is expected to rise to 40.31 million yuan in 2024, reflecting a significant year-on-year increase of approximately 48.9%, outpacing revenue growth. For the first nine months of 2025, profit was reported at 26.11 million yuan [3][8]. - The gross profit margin was 21.7% in 2023, improving to 23.3% in 2024, and stabilizing at 22.5% for the first nine months of 2025, indicating overall robust performance [9]. Group 3: Strategic Initiatives - Jinxin Healthcare is notably focused on integrating various elderly care assets under the China National Pharmaceutical Group, operating them under the unified platform "Jinxin Guosong." For instance, the Shanghai Guosong Elderly Care Center has been rebranded as "Jinxin Healthcare Shanghai Guosong Elderly Care Center" [4][9]. - The company is also responsible for a nursing home project within the Greenland International Elderly Care City in Qingpu, Shanghai, which is still in the implementation phase [10]. Group 4: Market Context and Future Outlook - Jinxin Group also operates another publicly listed company, Jinxin Reproductive (01951.HK), which holds five licenses for assisted reproduction, making it a leader among private institutions in China [5][11]. - The ongoing demographic trends of declining birth rates and accelerating aging populations present significant opportunities for Jinxin Healthcare. If the company successfully lists, it will create a full lifecycle capital loop from assisted reproduction to elderly care, which is significant for both the industry and the company [6][11]. - The capital strategy of Jinxin Group has consistently involved leveraging scarce licenses and employing a "merger and operational enhancement" approach for rapid expansion, ultimately leading to the path of listing [6][11].

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951.HK), has announced a board meeting scheduled for March 26, 2026, to consider and approve the annual performance for the fiscal year ending December 31, 2025 [1] Group 1 - The board meeting will focus on the approval of the group's annual results [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，本公司謹訂於2026年3月26日（星期四）舉行董事會會議，藉以 （其中包括）考慮及批准本集團截至2025年12月31日止年度的年度業績及其發佈。 承董事會命 錦欣生殖醫療集團有限公司* 首席執行官、代理首席財務官兼執行董事 董陽 香港，2026年2月23日 於本公告日期，本公司董事會包括執行董事董陽先生、呂蓉女士及耿麗紅博士；主席兼 非執行董事鍾勇先生；及非執行董事胡喆女士、嚴曉晴女士及陳樹云先生；以及獨立非 執行董事莊一強博士、李建偉先生、王嘯波先生及葉長青先生。 * 僅供識別 1951 董事會會議日期 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 2.727 million shares on February 13, 2026, while experiencing a net reduction of 13.909 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings in Jinxin Reproductive Medicine on 15 occasions, resulting in a total net increase of 24.1786 million shares [1] - As of now, southbound funds hold 1.461 billion shares of Jinxin Reproductive Medicine, accounting for 52.97% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [2] - The company's services are mainly provided in China and the United States [2]

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.8555 million shares on February 11, with a total net reduction of 5.5385 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a cumulative net increase of 19.0741 million shares [1] - As of now, southbound funds hold 1.466 billion shares of Jinxin Reproductive Medicine, accounting for 53.15% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, and maternal and pediatric medical services, as well as the sale of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Core Viewpoint - Southbound funds have increased their holdings in Jinxin Fertility (01951.HK), indicating growing investor interest in the company and its services in the assisted reproductive sector [1] Group 1: Shareholding Activity - On February 10, southbound funds increased their holdings by 679,000 shares of Jinxin Fertility [1] - Over the past five trading days, there have been four days of net increases in holdings, totaling 3.4365 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 20.0356 million shares [1] - Currently, southbound funds hold 1.471 billion shares of Jinxin Fertility, representing 53.33% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and obstetrics and pediatrics medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

Group 1 - Southbound funds reduced their holdings in Jinxin Fertility (01951.HK) by 4.7445 million shares on February 9 [1] - Over the past 5 trading days, southbound funds increased their holdings on 4 days, with a total net increase of 13.3475 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, totaling 13.3616 million shares [1] - Currently, southbound funds hold 1.47 billion shares of Jinxin Fertility, accounting for 53.31% of the company's issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]